Health & Medicine
High evidenceReview
Review finds no clear increase in digestive-tract tumors with SGLT2 drugs
Researchers combined results from 49 randomized controlled trials involving 49,054 people with type 2 diabetes to examine whether SGLT2 inhibitors were linked with gastrointestinal neoplasms, meaning tumors or abnormal growths in the digestive system. The analysis found no statistically significant association with gastrointestinal neoplasms overall or with the specific sites studied. However, about half of the trials lasted one year or less, so the analysis provides limited information about long-term risk.
·48 views
